<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200406046966N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-04-18</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Dexmedetomidine on patient's sedation and surgeon's satisfaction  during wisdom tooth surgery</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of patient's sedation and surgeon's satisfaction by applying the combination of Dexmedetomidine and Lidocaine during wisdom tooth surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-04-08</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>26</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47009</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: The randomization steps are as followed: for the first patient, two envelopes with the same appearance are selected, inside one of them there is a card on which dexmedetomidine in combination with lidocaine is written, and inside the other is a card on which lidocaine alone is written. Before the surgery, surgeon randomly selects one of the envelopes and only the researcher knows the content of envelope and the type of anesthesia isn't told to the surgeon prior to the start of injection and finishing the surgical procedure. After that, the surgeries are performed alternately. (Note that if for the first patient, surgery is performed by the combination of dexmedetomidine and lidocaine; for the opposite tooth surgery, lidocaine alone will be used and vice versa.), Blinding description: In this study, both participants and surgeon aren't aware of the type of anesthetic medications (in the other words, surgeon doesn't know for which patient uses the combination of dexmedetomidine and lidocaine or lidocaine alone) and only the researcher is aware of the cartridge combination. So, this study is double blinded.</study_design>
      <phase>3</phase>
      <hc_freetext>Mandibular impacted wisdom tooth.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, the patient undergoes local anesthesia with 10µg dexmedetomidine in combination with lidocaine 2% with epinephrine 1/80000. Cartridges are from Eksir brand. Each vial of Dexmedetomidine contains 2 ml (200µg) of the drug. /1 cc of each vial contains 10 µg of drug which is added to the cartridge of the intervention group with insulin syringe. Cartridges containing dexamedetomidine and lidocaine are similar to cartridges of lidocaine in terms of transparency. Intervention 2: Control group: The control group undergoes local anesthesia with lidocaine 2% with epinephrine 1/80000. Cartridges are from Eksir brand. To equalize the volume and appearance of the cartridges, /1 cc of normal saline is added to the cartridge of control group. Cartridges containing dexamedetomidine and lidocaine are similar to cartridges of lidocaine in terms of transparency.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared after patients are unrecognizable.

When:
6 months after the publication of the article

To whom:
Researchers working in academic institutions

Conditions:
Use of data under the supervision and agreement of the Isfahan University of Medical Sciences vice chancellor of Research and Technology and the project implementer and to achieve the intended aims in the proposal and developing review studies

Where to obtain:
Dr.Milad Etemadi: etemadi@dnt.mui.ac.ir

How to obtain:
1-Contact the project implementer via Email and make a written request for the consent to deliver the data 2-Seeking contact information of Isfahan University of Medical Sciences Vice Chancellor of research and Technology 3-Make a written request to obtain permission from Isfahan University of Medical Sciences Vice Chancellor of research and Technology 4-The data can be accessed only in person from the Department of Oral and Maxillofacial Surgery of Isfahan Dental School. If there is no problem, data will be accessible in 2 weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr.Milad Etemadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Oral and Maxillofacial Surgery, School of Dentistry, Isfahan University of Medical Sciences, Hezarjarib St., Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3792 5581</telephone>
        <email>etemadi@dnt.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Milad Etemadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Oral and Maxillofacial surgery department, School of Dentistry, Isfahan University of Medical Sciences, Hezarjarib St., Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3792 5581</telephone>
        <email>etemadi@dnt.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>According to the ASA physical status classification system, patient should be ASA I or ASA II (normal healthy patient or patient with mild systemic disease).
Patient with informed consent.
Patient's age should be between 18-30 years.
Patients should have two wisdom teeth (classified in the same class by Pell &amp; Gregory; mesioangular impaction, level B, class 1 or 2), which are similar in terms of surgical severity;
No general contraindications (in these patients use of dexmedetomidine is contraindicated: patients with low blood pressure, bradycardia, sinus disorder, unstable high blood pressure, arousability, tachyphylaxis and liver disorders.)
No lesions and malignancies at the surgical site;
No smoking.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient with wisdom tooth surgery on one side;
Occurring medical problems during surgery;
Patient who needs more than one cartridge injection;
Surgery lasting more than 20 minutes.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K01.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Impacted teeth</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, the patient undergoes local anesthesia with 10µg dexmedetomidine in combination with lidocaine 2% with epinephrine 1/80000. Cartridges are from Eksir brand. Each vial of Dexmedetomidine contains 2 ml (200µg) of the drug. /1 cc of each vial contains 10 µg of drug which is added to the cartridge of the intervention group with insulin syringe. Cartridges containing dexamedetomidine and lidocaine are similar to cartridges of lidocaine in terms of transparency.</i_keyword>
      <i_keyword>Control group: The control group undergoes local anesthesia with lidocaine 2% with epinephrine 1/80000. Cartridges are from Eksir brand. To equalize the volume and appearance of the cartridges, /1 cc of normal saline is added to the cartridge of control group. Cartridges containing dexamedetomidine and lidocaine are similar to cartridges of lidocaine in terms of transparency.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The patient's sedation rate. Timepoint: After the intervention. Method of measurement: Short Dental Fear Questionnaire.</prim_outcome>
      <prim_outcome>Surgeon's satisfaction. Timepoint: After the intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patient's cooperation level. Timepoint: After the intervention. Method of measurement: Data collection form.</sec_outcome>
      <sec_outcome>Evaluation of patient's satisfaction. Timepoint: After the intervention. Method of measurement: Visual Analogue Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-04-04</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar jarib St., Isfahan university of medical sciences Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
